Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cephalon, PsychoGenics Enter Neuro Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cephalon, PsychoGenics Enter Neuro Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PsychoGenics and Cephalon have entered into a drug discovery agreement. Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies.

The companies aim to jointly identify drug candidates suitable for clinical development. If Cephalon undertakes further development of the candidates, PsychoGenics will receive milestone payments and royalties. If PsychoGenics undertakes further development, it will make milestone and royalty payments to Cephalon.

Dr. Emer Leahy, president and chief executive officer of PsychoGenics, said, “We are delighted to partner with Cephalon and look forward to a successful collaboration. We are confident that combining Cephalon’s and PsychoGenics’ complementary strengths and expertise will enable us to identify a new generation of treatments for neuropsychiatric disorders.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics